Reference
- Moghadasian MH, Salen G, Frohlich JJ, et al. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol. 2002;59(4):527–529.
- Cali JJ, Hsieh CL, Francke U, et al. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991;266(12):7779–7783.
- Nie S, Chen G, Cao X, et al. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2014;9(1):179.
- Chen W, Kubota S, Teramoto T, et al. Silent nucleotide substitution in the sterol 27-hydroxylase gene (CYP 27) leads to alternative pre-mRNA splicing by activating a cryptic 5' splice site at the mutant codon in cerebrotendinous xanthomatosis patients. Biochemistry. 1998;37(13):4420–4428.
- Appadurai V, DeBarber A, Chiang P-W, et al. Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of 60,000 human exomes. Molec GenetMetab. 2015;116(4):298–304.
- Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med. 1984;311(26):1649–1652.
- Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol: Off J Eur Fed Neurol Soc. 2011;18(10):1203–1211.